A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia

Trial Profile

A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs ATR 101 (Primary)
  • Indications Congenital adrenal hyperplasia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Millendo Therapeutics
  • Most Recent Events

    • 08 Nov 2017 Status changed from active, no longer recruiting to discontinued, as reported in a Millendo Therapeutics media release.
    • 08 Nov 2017 According to a Millendo Therapeutics media release, enrollment in the trial was stopped at 10 patients. Full results will be presented at an upcoming medical meeting.
    • 08 Nov 2017 According to a Millendo Therapeutics media release, based on the trial results, the company ended the trial early and the U.S. Food and Drug Administration (FDA) has granted orphan drug status to ATR-101 in this indication.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top